Device For Detection Of Vitamin D Metabolites

Patent No. US11073524 (titled "Device For Detection Of Vitamin D Metabolites") was filed by Affimedix Inc on Jul 20, 2018.

What is this patent about?

’524 is related to the field of in-vitro diagnostics , specifically lateral flow assays for detecting and quantifying vitamin D levels in biological samples. Vitamin D deficiency is a widespread health concern, and accurate, rapid testing is needed. Existing methods like LC-MS/MS are accurate but time-consuming and require specialized laboratories. This invention aims to provide a simpler, faster, and more accessible method for determining vitamin D status.

The underlying idea behind ’524 is to use a sandwich immunoassay on a lateral flow strip to detect vitamin D. A vitamin D binding agent (antibody) on a conjugate pad binds to vitamin D in the sample. This complex then flows to a detection zone where a second antibody, specific to the complex formed between the vitamin D and the first antibody, is immobilized. The accumulation of the complex at the detection zone indicates the presence and quantity of vitamin D.

The claims of ’524 focus on a test device comprising a housing containing a sample application pad, a conjugate pad with a vitamin D binding agent, and a detection zone. The key feature is the detection zone, which has a region with an immobilized detection antibody that specifically binds to an epitope formed only when the vitamin D binding agent is complexed with vitamin D. The detection antibody is further defined by specific amino acid sequences for its light and heavy chains.

In practice, a biological sample (e.g., blood) is applied to the sample pad and migrates to the conjugate pad, where vitamin D binds to the vitamin D binding agent. This complex then flows along the strip to the detection zone. If vitamin D is present, the complex will be captured by the immobilized detection antibody, leading to a visible signal (e.g., from gold nanoparticles attached to the vitamin D binding agent). The intensity of the signal correlates with the vitamin D concentration in the sample.

This approach differs from prior methods by using a complex-specific antibody as the detection agent. Instead of directly capturing vitamin D or the vitamin D binding agent, the detection antibody only binds to the unique structure formed when they are combined. This potentially increases the assay's specificity and reduces background noise, leading to more accurate and reliable results. The lateral flow format also provides a rapid and user-friendly testing platform suitable for point-of-care applications.

How does this patent fit in bigger picture?

Technical landscape at the time

In the mid-2010s when ’524 was filed, lateral flow assays were at a time when they were typically implemented using a series of aligned pads or membranes to facilitate fluid flow and reagent interaction. At that time, it was common to use labeled binding agents, such as antibodies conjugated to gold nanoparticles or latex particles, for detection. Quantifying the results often relied on visual inspection or simple optical readers, when hardware or software constraints made more sophisticated image analysis non-trivial.

Novelty and Inventive Step

The examiner approved the application because the prior art did not specifically teach a test device that includes an antibody comprising both a light chain with a sequence from SEQ ID NOs 1-5 or 16-20 and a heavy chain with a sequence from SEQ ID NOs 6-15, as recited in claim 1.

Claims

This patent contains 23 claims, with claim 1 being the only independent claim. Independent claim 1 is directed to a test device for detecting vitamin D molecules, focusing on the device's components and their interactions. The dependent claims generally elaborate on and refine the features of the test device and related methods, including specific vitamin D molecules, detection methods, quantification steps, and kit components.

Key Claim Terms New

Definitions of key terms used in the patent claims.

Term (Source)Support for SpecificationInterpretation
Conjugate pad
(Claim 1)
“In one aspect, the present invention provides for a test device for detecting one or more vitamin D molecules comprising: (a) a housing, contained therein: (i) a sample application pad configured to absorb a biological sample and transport the biological sample to a conjugate pad; (ii) the conjugate pad comprising a vitamin D binding agent that specifically binds to one or more vitamin D molecules; and (iii) a detection zone comprising a first region immobilized therein a detection antibody that specifically binds an epitope that is generated by complexing the vitamin D binding agent with the one or more vitamin D molecules.”A component of the test device that contains a vitamin D binding agent, which specifically binds to one or more vitamin D molecules.
Detection agent
(Claim 1)
“In one aspect, the present invention provides for a test device for detecting one or more vitamin D molecules comprising: (a) a housing, contained therein: (i) a sample application pad configured to absorb a biological sample and transport the biological sample to a conjugate pad; (ii) the conjugate pad comprising a vitamin D binding agent that specifically binds to one or more vitamin D molecules; and (iii) a detection zone comprising a first region immobilized therein a detection antibody that specifically binds an epitope that is generated by complexing the vitamin D binding agent with the one or more vitamin D molecules.”An antibody that binds specifically to an epitope formed when a vitamin D binding agent complexes with one or more vitamin D molecules.
Detection zone
(Claim 1)
“In one aspect, the present invention provides for a test device for detecting one or more vitamin D molecules comprising: (a) a housing, contained therein: (i) a sample application pad configured to absorb a biological sample and transport the biological sample to a conjugate pad; (ii) the conjugate pad comprising a vitamin D binding agent that specifically binds to one or more vitamin D molecules; and (iii) a detection zone comprising a first region immobilized therein a detection antibody that specifically binds an epitope that is generated by complexing the vitamin D binding agent with the one or more vitamin D molecules.”A region within the housing of the test device where the presence of vitamin D molecules is indicated by the binding of a detection agent to a complex of vitamin D and a vitamin D binding agent.
Sample application pad
(Claim 1)
“In one aspect, the present invention provides for a test device for detecting one or more vitamin D molecules comprising: (a) a housing, contained therein: (i) a sample application pad configured to absorb a biological sample and transport the biological sample to a conjugate pad; (ii) the conjugate pad comprising a vitamin D binding agent that specifically binds to one or more vitamin D molecules; and (iii) a detection zone comprising a first region immobilized therein a detection antibody that specifically binds an epitope that is generated by complexing the vitamin D binding agent with the one or more vitamin D molecules.”A component of the test device that receives a biological sample and facilitates its movement to the conjugate pad.
Vitamin D binding agent
(Claim 1)
“In one aspect, the present invention provides for a test device for detecting one or more vitamin D molecules comprising: (a) a housing, contained therein: (i) a sample application pad configured to absorb a biological sample and transport the biological sample to a conjugate pad; (ii) the conjugate pad comprising a vitamin D binding agent that specifically binds to one or more vitamin D molecules; and (iii) a detection zone comprising a first region immobilized therein a detection antibody that specifically binds an epitope that is generated by complexing the vitamin D binding agent with the one or more vitamin D molecules.”A substance within the conjugate pad that selectively attaches to vitamin D molecules.

Patent Family

Patent Family

File Wrapper

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

US11073524

AFFIMEDIX INC
Application Number
US16041582
Filing Date
Jul 20, 2018
Status
Granted
Expiry Date
Oct 16, 2037
External Links
Slate, USPTO, Google Patents